Scholarlink

<p>Human epidermal growth factor receptor 2 (HER-2) serves as a pivotal target for breast cancer treatment and a vital prognostic marker. Anti-HER-2 therapies, which are integral to the management of HER-2-positive breast cancer, including monoclonal antibodies (e.g., trastuzumab and pertuzumab), tyrosine kinase inhibitors (e.g., lapatinib and pyrotinib), and antibody–drug conjugates (ADCs) such as trastuzumab emtansine (T-DM1). ADCs consist of a monoclonal antibody, a linker, and a cytotoxic payload, engineered to deliver chemotherapy selectively to tumor cells, thereby reducing the systemic toxicity associated with traditional chemotherapy. T-DM1, a HER-2-targeting ADC, combines the humanized anti-HER-2 IgG1 trastuzumab with DM1, a cytotoxic agent that inhibits microtubule formation. T-DM1 has significantly enhanced the prognosis of HER-2-positive breast cancer patients who fail to achieve a pathological complete response or develop distant metastases after neoadjuvant trastuzumab and pertuzumab therapy. While the combination therapy of T-DM1 with radiotherapy demonstrates an acceptable safety profile overall, clinicians should remain vigilant regarding potential severe treatment-related toxicities that have been observed in specific clinical scenarios. Nevertheless, limited research exists regarding the adverse effects and mechanisms of T-DM1 in combination with radiotherapy. This review investigates preclinical studies on the interactions between T-DM1 and radiotherapy, investigates associated adverse effects and their underlying mechanisms, identifies predictive factors and prognostic implications, and explores potential therapeutic strategies involving the concurrent T-DM1 with radiotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

T-DM1 with concurrent radiotherapy in HER2-positive breast cancer: preclinical evaluation and mechanisms, prediction, and exploration of adverse effects

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月22日

查看全文
  • Guangmin Wan,
  • Lu Yang,
  • Quan Wang,
  • Gang Xu

摘要

Human epidermal growth factor receptor 2 (HER-2) serves as a pivotal target for breast cancer treatment and a vital prognostic marker. Anti-HER-2 therapies, which are integral to the management of HER-2-positive breast cancer, including monoclonal antibodies (e.g., trastuzumab and pertuzumab), tyrosine kinase inhibitors (e.g., lapatinib and pyrotinib), and antibody–drug conjugates (ADCs) such as trastuzumab emtansine (T-DM1). ADCs consist of a monoclonal antibody, a linker, and a cytotoxic payload, engineered to deliver chemotherapy selectively to tumor cells, thereby reducing the systemic toxicity associated with traditional chemotherapy. T-DM1, a HER-2-targeting ADC, combines the humanized anti-HER-2 IgG1 trastuzumab with DM1, a cytotoxic agent that inhibits microtubule formation. T-DM1 has significantly enhanced the prognosis of HER-2-positive breast cancer patients who fail to achieve a pathological complete response or develop distant metastases after neoadjuvant trastuzumab and pertuzumab therapy. While the combination therapy of T-DM1 with radiotherapy demonstrates an acceptable safety profile overall, clinicians should remain vigilant regarding potential severe treatment-related toxicities that have been observed in specific clinical scenarios. Nevertheless, limited research exists regarding the adverse effects and mechanisms of T-DM1 in combination with radiotherapy. This review investigates preclinical studies on the interactions between T-DM1 and radiotherapy, investigates associated adverse effects and their underlying mechanisms, identifies predictive factors and prognostic implications, and explores potential therapeutic strategies involving the concurrent T-DM1 with radiotherapy.